

PURPOSE:

To describe the COVID-19 Associated Risks and Effects in Myasthenia Gravis (CARE-MG) policy on submitting manuscripts and abstracts for reporting results from the CARE-MG registry. This includes primary and secondary papers, as defined. CARE-MG, a physician-reported registry, is a joint effort of the International MG/COVID-19 Working Group and neurologists from across the globe to capture outcomes of people with myasthenia gravis (MG) who have developed COVID-19. This registry was officially formally launched on 09 April 2020. The policy may also apply to any CARE-MG related publications that arise pertinent to operations (e.g., registry overview/protocol design, operations, and recruitment updates, etc.)

POLICY:

Timely publication of major findings is central to the mission of the CARE-MG Study Group and the International MG/COVID-19 Working Group, and is the primary metric of our collective accomplishments. CARE-MG publications include manuscripts, abstracts, and presentations that report study findings and conclusions as well as operational aspects/challenges during times of crisis. We expect for our work to result in at least one peer-reviewed manuscript and include a presentation of study results at national and international meetings. Additionally, we realize that without robust international participation and collaboration that our investigation would not be possible. As such, our policy will ensure that all contributing physicians will be offered authorship as members of the CARE-MG Study Group.

Primary and secondary manuscripts:

Primary manuscripts are those written by study/steering committee members or writing group describing results and analysis of the primary and secondary aims of the study (i.e., analyses to be addressed in a formal study Statistical Analysis Plan, SAP).

Secondary manuscripts are those arising from secondary analysis of data by members of the study/steering committee or writing group, analysis of released study data by other investigators, and methodological papers. Provisions may also be made to allow secondary manuscripts reporting subgroup analyses based on SAP for specific regions/countries (i.e., Europe, North America, UK, Japan, etc.).

Abstracts for posters/oral presentation:

Abstracts, posters, and oral presentations are those prepared for presentations at professional meetings that will utilize data from the CARE-MG registry.

Reviews of Different Types of ManuscriptsPrimary Results:

- Steering Committee as per CARE-MG Publications policy

Secondary Analysis Results:

- Steering Committee as per CARE-MG Publications policy

Main Study Methods/Design Paper:

- Steering Committee as per CARE-MG Publications policy

Derivative Papers: (example: multi-center methodological implementation)

- Steering Committee as per CARE-MG Publications policy

PROCEDURE:**1. Notification for Primary Paper and Timetable for Development**

A writing team, designated by the CARE-MG Steering Committee and charged with reporting findings, must be finalized within four (4) weeks of notification that data is ready for manuscript development. The primary manuscript should be developed within 3 months of the data being made available for analysis in collaboration with study statistician. All secondary papers will be developed with steering committee involvement to ensure study reporting integrity and analyses vetted by statistician.

2. Authorship on primary result papers

- All articles utilizing data on patients recruited must acknowledge support from CARE-MG Study Group and all other possible future study sponsors (i.e., grant support for analysis) , unless advised by the sponsors that an acknowledgement is not necessary.
- Authorship for manuscripts will reflect investigators who have made substantial intellectual contributions to the research and its report, according to published guidelines: <http://www.icmje.org/index.html#authorship>. For each manuscript, a writing team and a list of

authors will be generated based on intellectual contributions, steering committee recommendations and accrual. All contributing physicians will be listed as authors as members of the CARE-MG Study Group. Authors not included as primary authors will be listed in the author appendix and included in all appropriate publications, which includes approval of manuscript for submission.

- Authorship must be agreed upon by the writing group of each manuscript and approved by the Steering Committee.

3. Authorship on Secondary Papers

Authorship on papers arising from secondary analysis of data should be decided by those who proposed the project, subject to approval by the CARE-MG Steering Committee. Each paper of such a study should be accompanied by a written statement of manuscript and authorship approval.

4. Authorship of Invited Papers

Authorship on invited reviews and chapters should be decided by the invitee. The Steering Committee has to, in writing, approve the writing of such an invited review or chapter. The CARE-MG Study Group should be acknowledged in all such invited reviews and chapters. All invited reviews and chapters should be sent to the Steering Committee.

5. Final Approvals

Primary and secondary manuscripts emanating from CARE-MG data should be submitted to the Steering Committee. Following approval of authorship, the paper can be submitted to Journal. It is the responsibility of the Steering Committee to ensure appropriate authorship for primary and secondary papers, as well as for invited articles or reviews.

Once co-authorship has been finalized, a final or near final draft will be circulated to ensure that all co-authors have had the opportunity to review and comment on the paper prior to submission. All authors will be allowed 14 days to complete these tasks in order to remain listed as co-authors.

The final draft of the manuscript is to be submitted to the journal by the corresponding author. A copy should be sent to the Steering Committee.

Publication Policy: Manuscripts and Abstracts for the CARE-MG Study Group.

Version 1.0
Effective Date: 11 May 2020

Abstracts for Oral/Poster Presentation

Draft abstracts shall be submitted to the Steering Committee by the lead author at least seven (7) days prior to submission. Authors of abstracts are to ensure that all co-authors have had an opportunity to review the abstract prior to submission.

Tracking of Publications and Presentations

It is the responsibility of the Steering Committee to track all CARE-MG related publications emanating from this dataset including clinical, qualitative, correlative study, statistical and computing abstracts and manuscripts and provide such information to the CARE-MG Study Group and International MG/COVID-19 Working Group on a quarterly basis.